Teladoc price target raised to $13 from $11 at Piper Sandler

Piper Sandler raised the firm’s price target on Teladoc (TDOC) to $13 from $11 and keeps an Overweight rating on the shares following a Fireside Chat with CEO Chuck Divita and CFO Mala Murthy. The firm believes CY24 chronic care headwinds are transitory and expects Integrated Care segment growth to return to mid-single digits after a transition year in CY25.